---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013837"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:08:06.265857+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma reports 2025 net loss of $8.8M ($0.78/sh); cash $7.7M; norovirus challenge study underway

## Summary
- Net loss $8.8M ($0.78/sh) vs $17.5M ($1.72/sh) in 2024; R&D spend down to $5.1M from $12.5M.
- Unrestricted cash $7.7M at Dec 31, 2025 vs $9.9M a year earlier; working capital $5.9M.
- Phase 1b norovirus challenge study of CDI-988 underway at Emory; first cohort evaluating GII.2 strain.
- CDI-988 is first oral antiviral candidate for norovirus; no approved treatments/vaccines exist; $60B global burden.
- Influenza CC-42344 Phase 2a completed; efficacy not reported due to trial conduct; plans for additional Phase 2a study.

## SEC filing metadata
- accession: 0001493152-26-013837
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/0001493152-26-013837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013837
- JSON: https://secwatch.observer/filing/0001493152-26-013837.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013837.txt

## Key facts
- Earnings Releases
  Cocrystal Pharma, Inc. reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the year ended December 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/0001493152-26-013837-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.